Eszopiclone
... The primary endpoint was the average sleep latency over the last three months of the first six months of the study. The secondary endpoint was total sleep time over the same time period. These data were not presented ordiscussed. The authors stated that seven other time points (weekone, and monthly ...
... The primary endpoint was the average sleep latency over the last three months of the first six months of the study. The secondary endpoint was total sleep time over the same time period. These data were not presented ordiscussed. The authors stated that seven other time points (weekone, and monthly ...
Product Monograph CEFTIN
... Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents including CEFTIN® (see ADVERSE REACTIONS). CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symp ...
... Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents including CEFTIN® (see ADVERSE REACTIONS). CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symp ...
PRODUCT MONOGRAPH ACCUTANE™ ROCHE isotretinoin
... compliance packaging. This “Patient Information” asks female patients of childbearing potential, who have not been counselled using Hoffmann-La Roche PREGNANCY PREVENTION PROGRAM, to contact their physician for further information. All patient materials and physician materials can be downloaded from ...
... compliance packaging. This “Patient Information” asks female patients of childbearing potential, who have not been counselled using Hoffmann-La Roche PREGNANCY PREVENTION PROGRAM, to contact their physician for further information. All patient materials and physician materials can be downloaded from ...
Prescribing Information
... abnormal liver tests, ACTOS should be initiated with caution. Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. In this clinical context, if the patient is found to have ...
... abnormal liver tests, ACTOS should be initiated with caution. Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. In this clinical context, if the patient is found to have ...
- Worcestershire Acute Hospitals NHS Trust
... have electronic access to) within the individual chemotherapy units. These areas will have available the mechanical drug delivery devices required for the safe administration of chemotherapy. These devices will have annual maintenance checks or more often if deemed appropriate. These devices will on ...
... have electronic access to) within the individual chemotherapy units. These areas will have available the mechanical drug delivery devices required for the safe administration of chemotherapy. These devices will have annual maintenance checks or more often if deemed appropriate. These devices will on ...
Development of a facile antibody–drug conjugate
... resulting in the exchange of the linker–drug with thiol-containing molecules such as albumin.4 This not only leads to premature loss of ADC molecules from circulation but also causes toxic side effects.12 There is an imperative need to improve upon the conventional linker technologies with a goal to ...
... resulting in the exchange of the linker–drug with thiol-containing molecules such as albumin.4 This not only leads to premature loss of ADC molecules from circulation but also causes toxic side effects.12 There is an imperative need to improve upon the conventional linker technologies with a goal to ...
Assessment report - Voncento - HUMAN COAGULATION FACTOR
... Prevention and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Voncento 250 IU/600 IU is indicated in adults and in adolescents from 12-18 years. Haemophilia A (congenital FVIII deficiency): Prophylaxis ...
... Prevention and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Voncento 250 IU/600 IU is indicated in adults and in adolescents from 12-18 years. Haemophilia A (congenital FVIII deficiency): Prophylaxis ...
International Narcotics Control Board
... The regular analysis of consumption data, particularly regarding narcotic drugs, convinced the Board that the level of consumption of narcotic drugs was very low in a number of countries. Therefore, in 1989, the Board, in cooperation with WHO, assessed the medical need for opiates in the world. They ...
... The regular analysis of consumption data, particularly regarding narcotic drugs, convinced the Board that the level of consumption of narcotic drugs was very low in a number of countries. Therefore, in 1989, the Board, in cooperation with WHO, assessed the medical need for opiates in the world. They ...
EFFECT OF CARVEDILOL ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF GLIPIZIDE Research Article
... action or both. Patients with diabetes mellitus are more susceptible to the vascular complications of hypertension and heart failure. Diabetes is the largest morbidity of patients with heart failure and being a major risk factor for cardiovascular disease 1. Cardiovascular disease is responsible for ...
... action or both. Patients with diabetes mellitus are more susceptible to the vascular complications of hypertension and heart failure. Diabetes is the largest morbidity of patients with heart failure and being a major risk factor for cardiovascular disease 1. Cardiovascular disease is responsible for ...
Consolidated List of Products Whose Consumption and/or Sale
... countries, who may not have easy access to the Internet or for those who would like to continue to receive the publication in the printed version for reasons of their own. In this regard, it should be understood that to obtain complete coverage, the present issue could only be used in conjunction wi ...
... countries, who may not have easy access to the Internet or for those who would like to continue to receive the publication in the printed version for reasons of their own. In this regard, it should be understood that to obtain complete coverage, the present issue could only be used in conjunction wi ...
View the 2016 Prior Authorization Criteria
... AFINITOR AFINITOR, AFINITOR DISPERZ All FDA-approved indications not otherwise excluded from Part D, lung neuroendocrine tumors, Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, soft tissue sarcoma with one of the following three histologic subtypes: perivascular epithelioid cell tumors ( ...
... AFINITOR AFINITOR, AFINITOR DISPERZ All FDA-approved indications not otherwise excluded from Part D, lung neuroendocrine tumors, Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, soft tissue sarcoma with one of the following three histologic subtypes: perivascular epithelioid cell tumors ( ...
Opioid Receptors and Legal Highs - The Salvia divinorum Research
... Little formal epidemiologic data are available for Salvia divinorum use, however, ethnographic investigations suggest a marked increase in the use of Salvia divinorum (16). Additional information was obtained from the Americal Association of Poison Control Centers. A search of the AAPCC data set fro ...
... Little formal epidemiologic data are available for Salvia divinorum use, however, ethnographic investigations suggest a marked increase in the use of Salvia divinorum (16). Additional information was obtained from the Americal Association of Poison Control Centers. A search of the AAPCC data set fro ...
Opioid Antagonists, Partial Agonists, and Agonists
... the management of opioid detoxification and treatment of withdrawal. All English language randomized controlled trials, observational trials, systematic reviews, and meta-analysis with more than 6 human subjects involving medications/therapies approved for use in the United States published between ...
... the management of opioid detoxification and treatment of withdrawal. All English language randomized controlled trials, observational trials, systematic reviews, and meta-analysis with more than 6 human subjects involving medications/therapies approved for use in the United States published between ...
Review of the Available Evidence on “Newer”
... Assessing the place in therapy of anticonvulsants is a challenging task due to the fact that most clinical trials on AEDs compare the active treatment with placebo and therefore direct comparisons among them are not always available. The relative efficacy of new compounds has to be inferred by means ...
... Assessing the place in therapy of anticonvulsants is a challenging task due to the fact that most clinical trials on AEDs compare the active treatment with placebo and therefore direct comparisons among them are not always available. The relative efficacy of new compounds has to be inferred by means ...
Application of Hepatocytes for In Vitro Uptake Studies
... and how low the pH must be for cationic (basic) drugs to be positively charged. ...
... and how low the pH must be for cationic (basic) drugs to be positively charged. ...
IBOGAINE IN THE TREATMENT OF HEROIN WITHDRAWAL ——Chapter 8——
... information about substance use history and past/current medical condition(s) was gathered and later cross-referenced for accuracy through a separate comprehensive psychosocial assessment. ...
... information about substance use history and past/current medical condition(s) was gathered and later cross-referenced for accuracy through a separate comprehensive psychosocial assessment. ...
Treatment of Pulmonary Arterial Hypertension
... Despite these improvements, approximately one response to one of these three drugs.1,40,41 third of patients with primary pulmonary hypertension die within three years after diagnosis.8 Intravenous epoprostenol improved exercise tolerance, prostacyclin therapy hemodynamics, and long-term survival in ...
... Despite these improvements, approximately one response to one of these three drugs.1,40,41 third of patients with primary pulmonary hypertension die within three years after diagnosis.8 Intravenous epoprostenol improved exercise tolerance, prostacyclin therapy hemodynamics, and long-term survival in ...
Warfarin-herb interactions: a review and study based on assessment
... adults in developed countries and more than 60% Asians use herb as an alternative medicines (Zhou, 2007; Anonymous, 2006). Despite widespread use of herbal remedies, scientific data about their safety and efficacy are lacking in most cases plus reporting of adverse drug events is currently limited. ...
... adults in developed countries and more than 60% Asians use herb as an alternative medicines (Zhou, 2007; Anonymous, 2006). Despite widespread use of herbal remedies, scientific data about their safety and efficacy are lacking in most cases plus reporting of adverse drug events is currently limited. ...
HTA Lowering blood pressure to prevent myocardial infarction and stroke:
... that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics ...
... that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics ...
Drug utilisation sub-committee (DUSC)
... Statistics published by the Australian Bureau of Statistics [3]. The analyses use the population estimate for 1 June of the relevant calendar year. The figures for 2014 used the population from 1 June 2013. Rolling annual averages are presented in some of the figures where there are substantial mont ...
... Statistics published by the Australian Bureau of Statistics [3]. The analyses use the population estimate for 1 June of the relevant calendar year. The figures for 2014 used the population from 1 June 2013. Rolling annual averages are presented in some of the figures where there are substantial mont ...
Glucosamine sulfate.fm
... supplements may contain glucosamine hydrochloride, whose treatment effects are much less well characterized, as will be discussed. In addition, several dietary supplements have appeared that claim glucosamine sulfate content, but that may be different from the prescription product described below. F ...
... supplements may contain glucosamine hydrochloride, whose treatment effects are much less well characterized, as will be discussed. In addition, several dietary supplements have appeared that claim glucosamine sulfate content, but that may be different from the prescription product described below. F ...
11146002
... concentration for a definite period of time. The quality of a drug is an important factor which ensures the health and wellness of a patient. Substandard quality of drugs increases the mortality and morbidity in a country. The objective of this project is to evaluate the quality of drug available in ...
... concentration for a definite period of time. The quality of a drug is an important factor which ensures the health and wellness of a patient. Substandard quality of drugs increases the mortality and morbidity in a country. The objective of this project is to evaluate the quality of drug available in ...
Two Decades Coordinating Medication Safety Efforts
... decades as a drug standards-setting organization and its experience with the nationwide USP- the Institute for Safe Medication Practices (ISMP) Medication Errors Reporting (MER) Program, the USP recognized that there were many causes for medication errors and no one organization was equipped to addr ...
... decades as a drug standards-setting organization and its experience with the nationwide USP- the Institute for Safe Medication Practices (ISMP) Medication Errors Reporting (MER) Program, the USP recognized that there were many causes for medication errors and no one organization was equipped to addr ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.